Abstract | BACKGROUND: METHODS: In this multicentre, open-label, phase 3 study, 61 children aged 2 to <15 years were treated with FFNS 55 μg, once daily for 12 weeks. Nasal and ocular symptoms were scored by parents/guardians/patients and recorded in a patient's daily diary. In addition, rhinoscopy findings, including mucosal swelling, were scored by the investigators as an efficacy measure. As a safety measure, adverse events and clinical laboratory data were evaluated. RESULTS: An adverse event was reported by 67% of patients during the treatment and follow-up period, all of which were mild in intensity. The most commonly reported adverse events were nasopharyngitis and acute sinusitis (acute rhinosinusitis). There were no serious adverse events. FFNS 55 μg improved nasal symptom scores and rhinoscopy findings compared with the baseline. Ocular symptom scores were also improved compared with the baseline in FFNS 55 μg in a sub-group of patients with any ocular symptoms at baseline. FFNS 55 μg was shown to be well tolerated over the 12-week treatment period. Majority of patients receiving FFNS 55 μg had unquantifiable plasma levels of fluticasone furoate (FF). CONCLUSIONS: Twelve-week treatment with FFNS 55 μg, once daily, is well tolerated and effective with low systemic exposure in Japanese children aged 2 to <15 years with PAR.
|
Authors | Kimihiro Okubo, Arisa Okamasa, Gosuke Honma, Masaki Komatsubara |
Journal | Allergology international : official journal of the Japanese Society of Allergology
(Allergol Int)
Vol. 64
Issue 1
Pg. 60-5
(Jan 2015)
ISSN: 1440-1592 [Electronic] England |
PMID | 25572559
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Copyright | Copyright © 2014 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved. |
Chemical References |
- Androstadienes
- Nasal Sprays
- fluticasone furoate
|
Topics |
- Adolescent
- Androstadienes
(administration & dosage, adverse effects, pharmacokinetics)
- Asian People
- Child
- Child, Preschool
- Female
- Humans
- Japan
- Male
- Nasal Sprays
- Rhinitis, Allergic, Perennial
(drug therapy, immunology)
- Treatment Outcome
|